KA

Kandhaswamy Ashokkan Sengunthar

Active Director Designated Partner DIN 11859613
DIN 11859613 First appointment Jul 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Kandhaswamy Ashokkan Sengunthar

Kandhaswamy Ashokkan Sengunthar is a Designated Partner at Valerius Pharma Llp (since 2026).

DIN 11859613
Primary Designation Designated Partner
First Appointment 29 Jul 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner29 Jul 20262026Active

Board colleagues of Kandhaswamy Ashokkan Sengunthar

NameDINCompanyDesignation
Hemalatha Shaktivel Sengunthamudaliar11859615Valerius Pharma LlpDirector/Designated Partner
Kailashben Dilipbhai Patel11859614Valerius Pharma LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Valerius Pharma Llp
Premium access

Shareholding and investment profile for Kandhaswamy Ashokkan Sengunthar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kandhaswamy Ashokkan Sengunthar

Kandhaswamy Ashokkan Sengunthar currently holds 1 directorship: Valerius Pharma Llp (Designated Partner, since 29 Jul 2026).

Kandhaswamy Ashokkan Sengunthar was first appointed on 29 Jul 2026 as Designated Partner at Valerius Pharma Llp.

The current boards of Kandhaswamy Ashokkan Sengunthar's companies include Hemalatha Shaktivel Sengunthamudaliar (Valerius Pharma Llp), Kailashben Dilipbhai Patel (Valerius Pharma Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available